Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.02.02.478913

Reliable and efficient parameter estimation using approximate continuum limit descriptions of stochastic models

Abstract

Stochastic individual-based mathematical models are attractive for modelling biological phenomena because they naturally capture the stochasticity and variability that is often evident in biological data. Such models also allow us to track the motion of individuals within the population of interest. Unfortunately, capturing this microscopic detail means that simulation and parameter inference can become computationally expensive. One approach for overcoming this computational limitation is to coarse-grain the stochastic model to provide an approximate continuum model that can be solved using far less computational effort. However, coarse-grained continuum models can be biased or inaccurate, particularly for certain parameter regimes. In this work, we combine stochastic and continuum mathematical models in the context of lattice-based models of two-dimensional cell biology experiments by demonstrating how to simulate two commonly used experiments: cell proliferation assays and barrier assays. Our approach involves building a simple statistical model of the discrepancy between the expensive stochastic model and the associated computationally inexpensive coarse-grained continuum model. We form this statistical model based on a limited number of expensive stochastic model evaluations at design points sampled from a user-chosen distribution, corresponding to a computer experiment design problem. With straightforward design point selection schemes, we show that using the statistical model of the discrepancy in tandem with the computationally inexpensive continuum model allows us to carry out prediction and inference while correcting for biases and inaccuracies due to the continuum approximation. We demonstrate this approach by simulating a proliferation assay, where the continuum limit model is the well-known logistic ordinary differential equation, as well as a barrier assay where the continuum limit model is closely related to the well-known Fisher-KPP partial differential equation. We construct an approximate likelihood function for parameter inference, both with and without discrepancy correction terms. Using maximum likelihood estimation, we provide point estimates of the unknown parameters, and use the profile likelihood to characterise the uncertainty in these estimates and form approximate confidence intervals. For the range of inference problems considered, working with the continuum limit model alone leads to biased parameter estimation and confidence intervals with poor coverage. In contrast, incorporating correction terms arising from the statistical model of the model discrepancy allows us to recover the parameters accurately with minimal computational overhead. The main tradeoff is that the associated confidence intervals are typically broader, reflecting the additional uncertainty introduced by the approximation process. All algorithms required to replicate the results in this work are written in the open source Julia language and are available at GitHub.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Simpson, M. J., Baker, R. E., Buenzli, P. R., Nicholson, R., Maclaren, O. J.. 2022-02-04. Reliable and efficient parameter estimation using approximate continuum limit descriptions of stochastic models. https://doi.org/10.1101/2022.02.02.478913

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Design of colipids with controlled lateral distance of head group moieties for targeting strategies in the field of lipid-based nanoparticles

Lipid nanoparticles and liposomes are nanoparticle drug formulations which are firmly established in clinics. In order to expand their application and improve efficacy, surface modifications can be a key strategy, especially for cell specific targeting. Targeting can be achieved by integrating ligand functionalized lipids or lipidoids on the nanoparticle surface. In this case, not solely the targeting ligand itself, but also the structure of the whole targeting lipid/lipidoid can affect the interaction of the targeting ligand with the binding motive on cells. Especially, distal spacer structures between lipid anchor and ligand unit, often composed of polyethylene glycol chains, provide a certain distance of the ligand from the nanoparticle surface. A concept which is currently neglected is the control of the lateral distance between ligand structures on the nanoparticle. Herein we investigated the possibility to design lipidoids with a lateral spacer composed of polyethylene glycol units. We synthesized and characterized different lipidoids which provide a primary amine in the head group for possible ligand coupling. In our model lipidoids the head groups were functionalized with a paramagnetic probe to apply electron paramagnetic resonance (EPR) methods for the characterization of the lipidoid interaction with model nanoparticles, in our case liposomes. Continuous wave EPR was used to study the efficiency of the novel lipidoids to integrate into lipid bilayers of model liposomes, which was shown to depend on lipidoid structure and liposome composition. Furthermore, using double electron-electron resonance (DEER), we observed lipidoid conformational changes occurring upon integration into liposomes.

biophysics↗

Binding mechanisms of therapeutic antibodies to human claudin-18.2

Claudin-18.2 (CLDN18.2) is a tight junction component with highly restricted expression in the paracellular space of nonmalignant gastric epithelial cells. It becomes accessible on tumor cell surface during malignant transformation, making CLDN18.2 an attractive target for targeted therapies against gastric cancer. Recently, zolbetuximab has become the first FDA-approved monoclonal antibody that targets CLDN18.2 in advanced gastric cancer, and others like osemitamab have entered phase 3 clinical trials. However, the high-resolution structure of CLDN18.2 is lacking, and how CLDN18.2 is recognized by therapeutic antibodies remains undefined. Here, we report cryo-EM structures of human claudin-18.2 (hCLDN18.2) in complex with the Fab fragments of zolbetuximab and osemitamab, revealing the structure of hCLDN18.2 and its binding mechanism to the therapeutic antibodies. Further analyses reveal that three residues in the first extracellular loop of hCLDN18.2 that are different from human claudin-18.1 (hCLDN18.1) play a critical role in antibody binding. Our data elucidate the structural basis for selective binding of therapeutic antibodies to hCLDN18.2, which should aid rational design of next-generation immunotherapies targeting hCLDN18.2.

biophysics↗

Structural relationships between the SLC12 cotransporter C-terminal domain, universal stress proteins and adenylating enzymes

Several SLC12 cotransporters bind ATP in a cytoplasmic C-terminal domain (CTD). We analysed 16,192 CTD-containing SLC12 sequences and compared 42,845 representative structures to examine the relationship between this nucleotide site, universal stress proteins (USPs) and adenylating enzymes. In phosphorylated NKCC1, D891 and D927 lie near the ATP phosphate chain, while R801 and K889 form a basic phosphate-binding clamp. NKCC1 retains this arrangement, whereas KCC paralogs replace or lose several corresponding groups. In structural comparisons with USP and adenylating-enzyme references, both CTD lobes score between universal stress proteins and EC-annotated domains, and the two lobes form separate lineages that include bacterial transporters. Lobe-specific and nucleotide-frame comparisons place ATP in the corresponding structural region used for -phosphate chemistry by catalytic members of this fold. Published work on UspG provides a precedent for protein-bound AMP in a natural USP. In the examined SLC12 structures and USP models, candidate protein hydroxyls lack an in-line geometry for attack at ATP P. Protein adenylation would require a change in protein or nucleotide geometry, or a different acceptor. These results define a structural basis for testing conditional protein adenylation at SLC12 nucleotide sites. The required evidence is a covalent protein-AMP adduct, identification of its acceptor and measurement of the expected pyrophosphate coproduct, with soluble nucleotide analysis to distinguish accompanying ATP reactions.

biophysics↗